Skip to main content
DNA Labs India

Comprehensive Leukemia Panel (SNVs, Small INDELs and CNVs) Test

DNA Labs India | ISO 9001:2015 Certified

Comprehensive Leukemia Panel (SNVs, Small INDELs and CNVs) Test

Short Name: Comprehensive Leukemia Panel

Also known as: Leukemia Mutation Panel, Leukemia Genetic Profile Test, Leukemia NGS Panel, Comprehensive Hematologic Malignancy Panel, Leukemia SNV INDEL CNV Panel

Comprehensive Leukemia Panel (SNVs, Small INDELs and CNVs) Test test available at DNA Labs India for ₹33,000. Uses Next Generation Sequencing (NGS), Targeted Gene Panel Sequencing, Copy Number Variation Analysis on Blood samples. Results in Results are typically available within 15-21 working days from the date of sample receipt at the laboratory. Reports can be accessed through the online portal, email, or WhatsApp.. Free home collection in 300+ cities across India.

Next Generation Sequencing (NGS)All Ages🏠 Home Collection

✍️ Written By

🩺 Medically Reviewed By

Dr SULOCHANA HEMCHANDRA HOLLA

Dr SULOCHANA HEMCHANDRA HOLLA

Consultant Medical Geneticist · Reg: 8532

Last reviewed: September 7, 2026

Overview

The primary purpose of the Comprehensive Leukemia Panel is to identify actionable genetic mutations in leukemia cells that aid in accurate diagnosis, molecular classification, risk stratification, prognosis assessment, and targeted therapy selection. Detection of mutations such as FLT3-ITD, NPM1, and CEBPA helps classify AML subtypes, while TP53 and RUNX1 mutations indicate adverse prognosis. The CNV component detects chromosomal gains and losses that are critical in disease classification per WHO and ELN guidelines.

Test Code
67
CPT Code
81450
ICD Code
C95.9, C92.0, C91.0
Price
₹33,000
Sample Type
Blood
Result Time
Results are typically available within 15-21 working days from the date of sample receipt at the laboratory. Reports can be accessed through the online portal, email, or WhatsApp.
Fasting Required
No
Method
Next Generation Sequencing (NGS), Targeted Gene Panel Sequencing, Copy Number Variation Analysis
Step 1

Sample Collection

No special preparation or fasting is required. Ensure the patient has not received a recent blood transfusion (ideally wait 2-4 weeks post-transfusion). Inform the healthcare provider about any anticoagulant therapy.

Method: Venipuncture

Step 2

Laboratory Analysis

A trained phlebotomist will collect approximately 5 mL of venous blood into an EDTA (lavender-top) vacutainer tube using standard venipuncture technique. The tube will be gently inverted 8-10 times to mix with the anticoagulant.

Step 3

Report Delivery

Label the sample clearly with patient details, date, and time of collection. Store the sample at room temperature (15-25°C) and ensure it reaches the laboratory within 48 hours of collection. Avoid freezing the sample.

Timeline: Results are typically available within 15-21 working days from the date of sample receipt at the laboratory. Reports can be accessed through the online portal, email, or WhatsApp.

Patient Instructions

1
Before the Test:No specific preparation is required. Inform your doctor about any medications, recent transfusions, or ongoing treatments. A doctor's prescription or referral may be required.
2
During the Test:A simple blood draw of approximately 5 mL will be performed by a trained phlebotomist. The procedure takes about 5-10 minutes. Home collection is available at no additional cost across India.
3
After the Test:After blood collection, you may resume normal activities immediately. Mild soreness at the puncture site is common and resolves quickly. Apply pressure to the site for a few minutes after the draw.

About This Test

Who Should Get This Test

The primary purpose of the Comprehensive Leukemia Panel is to identify actionable genetic mutations in leukemia cells that aid in accurate diagnosis, molecular classification, risk stratification, prognosis assessment, and targeted therapy selection. Detection of mutations such as FLT3-ITD, NPM1, and CEBPA helps classify AML subtypes, while TP53 and RUNX1 mutations indicate adverse prognosis. The CNV component detects chromosomal gains and losses that are critical in disease classification per WHO and ELN guidelines.

How to Prepare

  • Collect 5 mL whole blood in an EDTA (lavender top) vacutainer.
  • Gently invert the tube 8-10 times immediately after collection.
  • Do not centrifuge the sample.
  • Store at room temperature (15-25°C).
  • Transport to the laboratory within 48 hours of collection.
  • Avoid hemolyzed or clotted samples.
  • Label the tube with patient name, date of birth, date and time of collection.

Doctor's Notes

Reviewed by — MBBS, MD (Medical Genetics) · Reg. No. 8532

"The Comprehensive Leukemia Panel is an indispensable tool in modern oncology practice. Identifying specific driver mutations such as FLT3-ITD, NPM1, and TP53 alterations at diagnosis allows us to stratify risk accurately and select targeted therapies that significantly improve patient outcomes. I routinely recommend this panel for all newly diagnosed acute leukemia patients as part of the initial workup, as well as for relapsed or refractory cases where the molecular landscape may have evolved. Early and precise molecular profiling can mean the difference between a standard chemotherapy regimen and a tailored treatment approach incorporating FLT3 inhibitors, IDH inhibitors, or other novel agents."

Last medically reviewed: September 7, 2026

Test Parameters & Specifications

Sample TypeBlood
Sample Volume5 mL EDTA whole blood
ContainerEDTA (Lavender Top) Vacutainer
Collection MethodVenipuncture

Sample Stability

Room Temperature (15-25°C)
Refrigerated (2-8°C)
Frozen (-20°C)
Sample Rejection Criteria:
  • Hemolyzed sample
  • Clotted sample
  • Sample collected in incorrect container (non-EDTA)
  • Insufficient sample volume (less than 2 mL)
  • Sample older than 48 hours at room temperature
  • Unlabeled or mislabeled sample

Understanding Your Results

The Comprehensive Leukemia Panel results indicate the presence or absence of specific genetic mutations across the analyzed gene set. Each detected variant is reported with its variant allele frequency (VAF), zygosity, and associated clinical significance based on current WHO classification and ELN risk stratification guidelines. Results should be interpreted by a qualified hematologist or oncologist in the context of the patient's complete clinical picture, including morphology, immunophenotype, and conventional cytogenetics.
📊

No mutations detected

No pathogenic or likely pathogenic variants were identified in the analyzed genes. This does not completely exclude leukemia, and correlation with clinical findings, morphology, and other diagnostic modalities is essential.

📊

Favorable-risk mutations (e.g., NPM1 without FLT3-ITD, biallelic CEBPA)

Detection of favorable-risk molecular markers suggests a better prognosis. These patients may achieve higher remission rates with standard induction chemotherapy. ELN 2022 guidelines classify these as favorable risk.

📊

Intermediate-risk mutations (e.g., DNMT3A, TET2, IDH1/IDH2)

These mutations contribute to an intermediate risk category. Treatment decisions should be based on the composite genetic profile and response to initial therapy. Targeted agents such as IDH inhibitors may be considered.

📊

Adverse-risk mutations (e.g., TP53, RUNX1, ASXL1)

Adverse-risk mutations are associated with poor response to standard chemotherapy and shorter overall survival. Allogeneic stem cell transplantation in first remission and/or novel therapeutic strategies should be considered.

📊

Actionable targetable mutations (e.g., FLT3-ITD, IDH1, IDH2, KIT)

Detection of mutations with available targeted therapies allows for personalized treatment planning. FLT3 inhibitors (midostaurin, gilteritinib), IDH inhibitors (ivosidenib, enasidenib), and other targeted agents may be incorporated into the treatment regimen.

⚠️ When to Consult a Doctor:

Consult your hematologist or oncologist immediately if you experience persistent fatigue, unexplained weight loss, frequent infections, easy bruising or bleeding, swollen lymph nodes, bone pain, or night sweats. If you have been diagnosed with leukemia and receive this panel report, discuss the molecular findings with your treating oncologist to understand risk classification and treatment options including targeted therapies.

Limitations

  • ⚠This panel targets specific known genes and may not detect novel or rare mutations outside the covered gene list.
  • ⚠Structural variants such as large translocations (e.g., t(15;17), t(8;21)) are not fully covered and may require additional FISH or cytogenetic analysis.
  • ⚠The panel does not replace conventional karyotyping or FISH studies, which should be performed alongside this test.
  • ⚠Subclonal mutations at very low variant allele frequencies (VAF) below the analytical sensitivity threshold may not be detected.
  • ⚠Results should always be interpreted in conjunction with clinical findings, morphology, immunophenotyping, and cytogenetic data.

Risks & Considerations

  • ●Minor bruising or discomfort at the venipuncture site
  • ●Rare risk of infection at the puncture site
  • ●Very rare risk of fainting during blood draw
  • ●False-negative results if leukemic cell burden is very low in the sample

Interfering Factors

  • ●Highly degraded or insufficient DNA quality from the sample
  • ●Sample contamination during collection or transport
  • ●Recent blood transfusion may dilute leukemic cell population
  • ●Low tumor burden in the sample may affect detection sensitivity
  • ●Presence of inhibitors in the sample affecting enzymatic reactions

Compare With Similar Tests

TestComprehensive Leukemia Panel (SNVs, Small INDELs and CNVs)Complete Blood Count (CBC)Bone Marrow Biopsy with CytogeneticsFLT3 Mutation Analysis (Single Gene)Flow CytometryBCR-ABL1 Fusion Gene Test
ComparisonComprehensive Leukemia Panel (SNVs, Small INDELs and CNVs)

Frequently Asked Questions

What is the Comprehensive Leukemia Panel?
The Comprehensive Leukemia Panel is an advanced next-generation sequencing (NGS)-based diagnostic test that analyzes DNA from blood or bone marrow samples to detect genetic mutations associated with leukemia. It covers single nucleotide variants (SNVs), small insertions and deletions (INDELs), and copy number variants (CNVs) across more than 40 genes commonly implicated in acute and chronic leukemias.
What types of mutations does this panel detect?
This panel detects three major types of genetic alterations: single nucleotide variants (SNVs) which are single base-pair changes, small insertions and deletions (INDELs) which involve the addition or loss of small DNA segments, and copy number variants (CNVs) which involve gains or losses of larger chromosomal segments. Together, these provide a comprehensive molecular profile of the leukemia.
Who should get the Comprehensive Leukemia Panel test?
This test is recommended for patients newly diagnosed with acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), or other suspected hematologic malignancies. It is also recommended for patients with relapsed or refractory leukemia, those requiring risk stratification before treatment, and individuals with abnormal blood counts suggestive of leukemia who need definitive molecular diagnosis.
What sample is required for this test?
The test requires approximately 5 mL of peripheral venous blood collected in an EDTA (lavender-top) vacutainer tube. In certain cases, a bone marrow aspirate sample may also be used if recommended by the treating physician. No fasting is required for this test.
How long does it take to get the results of the Comprehensive Leukemia Panel?
The turnaround time for this test is approximately 15 to 21 working days from the date the sample is received at the laboratory. The complexity of NGS-based analysis, bioinformatic processing, and variant interpretation requires this timeframe to ensure accuracy. Reports are delivered via the online portal, email, or WhatsApp.
What is the cost of the Comprehensive Leukemia Panel in India?
The cost of the Comprehensive Leukemia Panel at DNA Labs India is INR 33,000. This price includes home sample collection, NGS-based analysis of all targeted genes, comprehensive report generation, and online report access. There are no additional or hidden charges.
Is home sample collection available for this test?
Yes, DNA Labs India offers free home sample collection for the Comprehensive Leukemia Panel across India. You can book online and a trained phlebotomist will visit your location to collect the blood sample. This service is available in all major cities including Mumbai, Delhi, Bangalore, Hyderabad, Chennai, Kolkata, and many more.
How is this test different from a standard blood test for leukemia?
A standard blood test such as a CBC can detect abnormal blood cell counts and flag the possibility of leukemia, but it cannot identify the specific genetic mutations driving the disease. The Comprehensive Leukemia Panel uses NGS technology to analyze the DNA at a molecular level, identifying exact mutations that determine the leukemia subtype, prognosis, and most suitable targeted treatments. This test is performed after an initial blood test suggests a hematologic abnormality.
What genes are analyzed in this panel?
The panel analyzes over 40 genes commonly associated with leukemia, including but not limited to FLT3, NPM1, CEBPA, TP53, RUNX1, ASXL1, DNMT3A, IDH1, IDH2, TET2, KIT, JAK2, KRAS, NRAS, PHF6, SF3B1, SRSF2, U2AF1, ZRSR2, WT1, and GATA2. CNV analysis covers chromosomal regions associated with gains and losses relevant to leukemia classification.
Can this test detect all types of leukemia?
This panel is primarily designed for acute leukemias including AML and ALL, and also covers mutations relevant to myelodysplastic syndromes and myeloproliferative neoplasms that may transform into leukemia. However, for chronic myeloid leukemia (CML), a BCR-ABL1 fusion test is more specific. For chronic lymphocytic leukemia (CLL), a different gene panel may be more appropriate. Your doctor will recommend the most suitable test based on the clinical presentation.
Do I need a doctor's prescription for this test?
Yes, a doctor's prescription or referral is recommended for the Comprehensive Leukemia Panel, as the test results require clinical interpretation by a qualified hematologist or oncologist. If you do not have a prescription, DNA Labs India can assist you in connecting with a consulting physician who can evaluate your symptoms and provide the necessary referral.
What happens after the test results are available?
Once the results are available, your treating hematologist or oncologist will review the molecular findings and integrate them with your clinical data, morphology, immunophenotyping, and cytogenetic results. Based on the complete diagnostic picture, your doctor will discuss the risk classification, prognosis, and treatment options, including conventional chemotherapy, targeted therapies, or consideration for stem cell transplantation. Genetic counselling may also be recommended to help you understand the implications of the findings.
Worried about the process? Our certified phlebotomists collect thousands of samples every month across India. The process takes under 5 minutes and is virtually painless. Questions? Message us on WhatsApp — we're here 7 days a week.

Related Tests

CDKN1C Gene Beckwith-Wiedemann syndrome NGS Genetic Test

₹20,000

XRCC2 Gene Fanconi anemia, XRCCR2 related NGS Genetic Test

₹20,000

PTCH1 Gene Basal cell nevus syndrome NGS Genetic Test

₹20,000

ATR Gene Cutaneous telangiectasia and cancer syndrome, familial NGS Genetic Test

₹20,000

PTEN Gene Cowden syndrome type 1 NGS Genetic Test

₹20,000

MSH6 Gene Endometrial cancer, familial, MSH6 related NGS Genetic Test

₹20,000
For Hospitals & Clinics

Reference Laboratory Services

We serve as a reference laboratory for hospitals and clinics across India. Send samples from your facility with same-day pickup, priority processing, and results delivered through our online portal. Competitive institutional pricing available.

LIMS Integration

Your Data Privacy

Your medical data is protected under Indian law.

✓ Stored in India: All patient records are stored on servers located in India. No data is transferred outside the country.

✓ DPDP Act Compliant: Under the Digital Personal Data Protection Act 2023, you can request deletion of your records at any time by contacting support.

Book Your Test

Enter your details and we'll connect you within 15 minutes.

🧬

Quick Connect

Enter your mobile number and we’ll connect you with the team.

+91

✅ Connecting you now...

🔒 Your number is used to respond to this request.